#Oncology #ArtificialIntelligence #Cancer #NewTherapy
The integration of artificial intelligence (AI) in oncology marks
a revolution in the management of cancer patients. Thanks to its advanced
analytical capabilities, AI efficiently processes narrative data, which
constitute more than 80% of the information contained in electronic medical
records. These data, often difficult to exploit manually, include radiology
reports, clinical observations, and complex therapeutic protocols. By
structuring these data, AI facilitates clinical decision-making by organizing
and analyzing medical information. It helps personalize treatments and detect predictive
trends invisible to traditional methods.
However, despite these advances, the widespread adoption of AI in
oncology remains a challenge. Algorithmic biases are a major
concern, particularly when they stem from unrepresentative or incomplete
training data.
Additionally, clinical validation of these tools remains
insufficient. Questions persist regarding their reliability and
effectiveness in real-world environments. Finally, the interpretability
of AI models is a significant obstacle. Healthcare professionals hesitate
to adopt systems whose decision-making processes remain opaque, even
when they produce impressive results.
This study evaluates the effectiveness of natural language processing
(NLP) models in improving the interpretation and analysis of narrative
medical data in oncology. It examines their ability to predict
prognoses, recommend personalized treatments, and match patients to clinical
trials. In parallel, additional approaches such as federated learning
were explored to ensure data confidentiality and improve model
generalization. These tools were tested under real clinical conditions to
identify their limitations and areas for improvement.
Read next: AI-based pathology predicts origins for cancers of unknown primary
Can AI Truly Revolutionize Oncology?
To validate the effectiveness of these NLP models, they were
trained using supervised and transfer learning. Their efficiency was
measured by analyzing the following outcome variables: accuracy, patient
survival, and the relevance of therapeutic recommendations. The integration
of federated learning allowed institutions to collaborate without
directly sharing their data, ensuring confidentiality while improving model
generalization.
This study demonstrates that NLP models exhibit high accuracy,
sometimes surpassing human performance in predicting cancer progression and
recommending treatments. However, their clinical application remains
limited by challenges such as the lack of data standardization and
the management of errors in complex cases. These advances confirm AI’s
potential in oncology, while also highlighting the need for further
improvements to enable broader adoption.
Read next: L’IA dans le cancer du poumon non à petites cellules
AI and Cancer: A Revolution in Progress or an Illusion?
Cancer remains a leading cause of mortality worldwide,
necessitating continuous advancements to optimize diagnoses and
treatments. In this context, AI emerges as a powerful tool to
enhance oncology care, particularly through data analysis and personalized
treatments.
This study aimed to evaluate the effectiveness of AI models in
oncology, examining their ability to interpret medical data, predict
cancer progression, and recommend tailored treatments. It highlights both their
potential and current limitations.
The results indicate that AI can surpass human expertise in
certain tasks, such as prognosis prediction and patient matching for
clinical trials.
However, its clinical integration faces multiple
challenges. Biases in training data can distort predictions, and the
complexity of models hinders adoption. Moreover, the lack of
standardization and the opacity of algorithms pose risks, requiring
rigorous validation to ensure their safety and reliability. Finally, the
environmental footprint of complex models and the need to build trust
among clinicians slow down adoption.
In the future, multicenter evaluations and ethical integration
will be essential to ensure the reliability of these technologies. Stronger
regulations, combined with more explainable and eco-friendly models,
could make AI a central pillar of oncology, offering more precise,
personalized, and accessible treatments.
Read next: L’IA dans l’évaluation de l’adénocarcinome pulmonaire
